Loading company…
TargED Biopharmaceuticals develops targeted thrombolysis drugs for thrombosis-related conditions.
Founded in Utrecht in 2018, TargED Biopharmaceuticals develops biological drugs that use small antibodies to deliver enzymes to blood clots. Its lead product, Microlyse, targets a protein found in different forms of thrombosis, with potential applications including Thrombotic Thrombocytopenic Purpura. In December 2025, the company raised EUR 21.5 million in Series A funding led by BioGeneration Ventures, with participation from Andera Partners, Fund+, Hadean Ventures, Inkef, Sunstone Life Science Ventures, and Curie Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in